Navigation Links
'Prepped' by tumor cells, lymphatic cells encourage breast cancer cells to spread
Date:9/3/2014

Breast cancer cells can lay the groundwork for their own spread throughout the body by coaxing cells within lymphatic vessels to send out tumor-welcoming signals, according to a new report by Johns Hopkins scientists.

Writing in the Sept. 2 issue of Nature Communications, the researchers describe animal and cell-culture experiments that show increased levels of so-called signaling molecules released by breast cancer cells. These molecules cause lymphatic endothelial cells (LECs) in the lungs and lymph nodes to produce proteins called CCL5 and VEGF. CCL5 attracts tumor cells to the lungs and lymph nodes, and VEGF increases the number of blood vessels and makes them more porous, allowing tumor cells to metastasize and infiltrate the lungs.

In the same report, the researchers say maraviroc, a drug already approved for treating HIV infection, blocked the siren call of CCL5 in tests on animals and cells and prevented tumor spread (metastasis). Additional experiments using a combination of maraviroc and a drug that blocks the VEGF protein suggest that the treatment duo could be an effective way to prevent metastatic disease in human breast cancer patients, according to the researchers.

Because the anti-retroviral drug maraviroc has already been approved by the U.S. Food and Drug Administration and has been shown safe for long term, oral use, it could be tested in clinical trials sooner rather than later, says Aleksander Popel, Ph.D., a professor in the Department of Biomedical Engineering at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center.

"It was surprising to find that LECs can play such an active and significant role in tumor spread." Popel noted. "Conventionally, lymphatic vessels are regarded mainly as passive conduits through which tumor cells spread from the primary tumor and eventually metastasize," he said. "However, we now know that lymphatic vessels enable metastasis, and other studies also show that they play an important role in whether or not immune cells recognize and attack cancer cells."

Popel and colleagues traced the influence of tumor signaling on LECs in cell cultures and in mice. Breast cancer cells were bathed in a nutrient-rich liquid, and, as the cancer cells grew, the investigators detected secretions of a signaling molecule called interleukin-6 (IL6) in the liquid.

Mice that were injected with the IL6-containing liquid experienced a continual rise in CCL5 levels in blood samples for several weeks. Nine of 10 tumor-bearing mice injected with the IL6-laden liquid developed metastases five weeks later. Only two of 10 mice, exposed to the liquid and given a combination of maraviroc and a VEGF-blocking drug, developed metastases.

Because maraviroc blocks the actions of CCL5, it could be delivered, along with standard chemotherapy, right after surgically removing a tumor in a bid to prevent any leftover circulating tumor cells from finding a new metastatic niche in the body, Popel says.

"However, IL6-secreting tumors could be laying the groundwork for metastasis much earlier than surgery occurs in a patient," he said. "To prevent metastatic sites from taking root, we could administer drugs that block IL6 before surgery."

The study did not address when or how to remove lymph node tissue surgically, as is often done as part of breast cancer treatment, but Popel and colleagues hope to explore the issue in future studies.


'/>"/>

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine
Source:Eurekalert

Related medicine news :

1. ‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread
2. World Gardens Café Helps Busy Moms with Fully-Prepped Healthy Meals for the Whole Family
3. Skip the Fast Food on a Summer Road Trip with Fully-Prepped Meals from World Gardens Café
4. American Brain Tumor Association Supports $2 Million Glioblastoma Research Project
5. Handheld scanner could make brain tumor removal more complete, reducing recurrence
6. Atlantic NeuroSurgical Specialists (ANS) Introduce Noninvasive Treatment for Brain Tumor Patients
7. Circulating tumor cell clusters more likely to cause metastasis than single cells
8. American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators
9. Preclinical development of tumor therapeutic agent starts
10. Tumor blood vessel protein provides potential therapeutic target
11. High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... La. (PRWEB) , ... February 18, 2017 , ... ... released today provides the latest information and contact points to easily connect elderly ... home care, assisted living, and elder-care funding. It also conveys material on this ...
(Date:2/17/2017)... Murfreesboro, TN (PRWEB) , ... February 17, 2017 ... ... EHR mobility has not kept pace. Enovate Medical has introduced an innovative workstation ... 20 years of supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, ...
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... software tools that allow for the electronic prescribing of controlled and non-controlled substances ... , Ninety percent of pharmacies in the United States now accept electronic prescriptions, ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 ... manufacturers distinguish between corrective action (CA) and preventive action (PA)? , The methods ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... TOWN, South Africa , Feb. 20, 2017 /PRNewswire/ ... of illness and non-communicable diseases (NCDs) across sub-Saharan Africa, ... prescription drugs. The growing incidence of more Western lifestyle ... respiratory disease, in addition to infectious and parasitic illness, ... with a business opportunity of $40.8 billion ...
(Date:2/20/2017)... SAN FRANCISCO , February 20, 2017 /PRNewswire/ ... (CSF) management market  is anticipated to reach USD ... report by Grand View Research, Inc. Constant evaluation ... hydrocephalus management is expected to drive growth in ... the investment for development of novel and improved ...
(Date:2/20/2017)... 20, 2017 Acute, Chronic and Prophylaxis GVHD ... at a CAGR of 7% from 2016-2021 and CAGR of 3% from ... from 2016 to 2027. The market is estimated at $0.36bn in 2016, ... ... discover how you can exploit the future business opportunities emerging in this ...
Breaking Medicine Technology: